Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- March31 2003
- Volume 10
- Issue 6
NEWS YOU CAN USE: How's It Going?
Advertisement
In these times of falling investments, it helps for doctors to consider things from a long-term perspective. The financial numbers are still good:
Articles in this issue
about 18 years ago
WAR AND WALL STREETabout 18 years ago
THE 529 FACTSabout 18 years ago
A WILL THAT WORKSabout 18 years ago
WALL STREET WOESabout 18 years ago
FINANCIAL PLANNING KEYabout 18 years ago
MIXED SIGNALSabout 18 years ago
PAPERWORK REDUCTIONabout 18 years ago
SHRINKING GIFTSabout 18 years ago
Medicare Cuts Deniedabout 18 years ago
DID YOU KNOW…Advertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5